- Home
- NYT vs BBIO Comparison
NYT vs BBIO Comparison
Compare NYT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NYT | BBIO |
|---|---|---|
| Founded | 1851 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 12.7B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NYT | BBIO |
|---|---|---|
| Price | $70.75 | $70.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 25 |
| Target Price | $72.14 | ★ $86.33 |
| AVG Volume (30 Days) | 1.7M | ★ 2.7M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ 18.08 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $1,783,639,000.00 | $502,076,000.00 |
| Revenue This Year | $10.58 | $89.45 |
| Revenue Next Year | $6.98 | $73.78 |
| P/E Ratio | $127.15 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $51.03 | $41.80 |
| 52 Week High | $87.10 | $84.94 |
Technical Indicators
Market Signals| Indicator | NYT | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.61 | 57.91 |
| Support Level | $69.30 | $62.39 |
| Resistance Level | $71.78 | $71.74 |
| Average True Range (ATR) | 1.92 | 2.32 |
| MACD | -0.30 | 0.47 |
| Stochastic Oscillator | 24.37 | 67.48 |
Price Performance
Historical ComparisonAbout NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company derives revenue from subscriptions, advertising, and other sources, where the majority of its revenue is generated through subscriptions, which consist of income from standalone and multiproduct bundle subscriptions to its digital products and subscriptions to and single-copy and bulk sales of print products.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.